Background: NA-831 is a candidate for the treatment of Alzheimer's Disease (AD). NA-911 is an analog of NA-831, serving as an IGF-1 and GLP-1 agonists. Animal studies of NA-911 are evaluated for the treatment of by hypoxic-ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders METHOD: For NA-831: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo. The patients with MCI received 10 mg of NA-831 or placebo orally per day. The patients with mild and moderate AD received 30 mg of NA-831 or placebo orally per day. Subjects with MCI to meet the NIA-AA core clinical criteria, CDR score of 0.5 and a Memory Box score of 0.5 or greater at Screening and Baseline. MMSE score ≥22. Subjects with mild & moderate AD to meet the NIA-AA core clinical criteria. MMSE: 17-21. For NA-911: We conducted animal studies of NA-911 on adult male Sprague-Dawley rats using the middle coronary artery occlusion (MCAO) method. This method is designed to mimic neurological and behavioral signs and symptoms of stroke in humans. Details of the animal study method will be described.
Results: NA-831 showed a significant improvement for patients with mild and moderate AD with the ADAS-Cog-13 score change of an average of 4.1 as compared to the placebo after 24 weeks of treatment (p = 0.001; ITT). CIBIC-Plus showed 78% patients improved (p = 0.01; ITT). mNA-831 was well-tolerated at 30 mg/day. In the animal study of NA-911, the area of infarct in animals treated with vehicle was 43.4±7.4 mm (n = 13, Treatment with NA-911 (3 mg/kg/h) significantly reduced the area of the infarct to 17.3 ±5.4 mm when compared to its vehicle treated group (n = 15, * P<0.05). It has been shown that progenitor cells residing in the SVZ are potentially able to replace the loss of nervous tissue after stroke.
Conclusion: An association of Alzheimer's disease and stroke has been suggested with clinical studies of NA-831 and NA-911. However, whether this association is causal requires further evaluation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.095736 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brain iron deposition and cognitive decline in patients with cerebral small vessel disease : a quantitative susceptibility mapping study.
Alzheimers Res Ther
January 2025
Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA, Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Background: Quantitative susceptibility mapping (QSM) can study the susceptibility values of brain tissue which allows for noninvasive examination of local brain iron levels in both normal and pathological conditions.
Purpose: Our study compares brain iron deposition in gray matter (GM) nuclei between cerebral small vessel disease (CSVD) patients and healthy controls (HCs), exploring factors that affect iron deposition and cognitive function.
Materials And Methods: A total of 321 subjects were enrolled in this study.
Exposure to Chinese famine in early life and the risk of multimorbidity in adulthood.
BMC Public Health
January 2025
Public Health Research Center, Department of Public Health and Preventive Medicine, Wuxi School of Medicine, Jiangnan University, 1800 Lihu Road, Binhu District, Wuxi, 214122, Jiangsu Province, China.
Objectives: Previous studies had reported the association between famine exposure in early life and subsequent non-communicable diseases risk. In current study, we aimed to evaluate the associations between famine exposure on multimorbidity prevalence and incidence in middle-aged and older Chinese population.
Methods: A total of 13,254 participants from the China Health and Retirement Longitudinal Study 2011 were included in cross-sectional analyses.
Clinical characteristics, outcomes, and costs of COVID-19 patients in Thai hospitels: a comparative analysis based on chest X-ray findings.
BMC Infect Dis
January 2025
Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: "Hospitels" are hotels that have been specially converted to healthcare facilities. Their utilization emerged as a resource-optimization strategy during the peak of the COVID-19 pandemic in Thailand. This study evaluated the clinical characteristics, outcomes, and admission costs of asymptomatic and mild-to-moderate COVID-19 patients treated in these facilities.
View Article and Find Full Text PDFContinued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON.
Lung
January 2025
National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis (PPF), nintedanib slowed the decline in forced vital capacity (FVC) versus placebo, with a safety profile characterised mainly by gastrointestinal events. INBUILD-ON, the open-label extension of INBUILD, assessed the safety of nintedanib during longer-term treatment. Data on FVC were collected.
View Article and Find Full Text PDFPrednisolone versus antihistamine for allergic rhinitis: No significant difference found in randomized trial.
Clin Transl Allergy
January 2025
Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Background: Seasonal allergic rhinitis (AR) impacts public health by affecting work productivity and quality of life. The Swedish tree pollen season starts in February with alder and hazel pollination, followed by birch and ends with oak in May. Systemic corticosteroids are often prescribed when topical treatments fail, despite limited evidence supporting their efficacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!